Travis Wilson

Office Phone:

(617) 588-4900


  Pro - Try 1 Week Free
 

    and access,

  •     75K PE/M&A Contacts
  •     +
  •     4.5K PE Firms
  •     3.6K M&A Advisors
  •     191K Transactions
  •     196K Companies

  •     Market Services
  •     Build Lists
  •     Research Sectors
  •     Uncover Opportunities

Bio

Travis has more than 15 years of investing and executive experience in life sciences and biotechnology. Prior to joining GPC, Travis was President and CEO of Stealth BioTherapeutics (NASDAQ: MITO), a late-stage clinical company developing technologies to treat mitochondrial dysfunction in common and rare diseases. While CEO and for more than a decade, Travis was a member of the life sciences and biotechnology investment team at the Morningside Group, a privately-held investment firm. As an investor with Morningside, Travis was involved in several successful outcomes, including Chimerix (NASDAQ: CMRX), Genocea (NASDAQ: GNCA), BioVex (acquired by Amgen), Aduro (NASDAQ: DRO), Argos (NASDAQ: ARGS), Liquidia (NASDAQ: LQDA), Apellis (NASDAQ: APLS), and ACD (acquired by Bio-Techne). Travis has also served as a director and board member for multiple biopharmaceutical companies, providing operational and management support to a portfolio of companies developing drugs across a broad spectrum of therapeutic focus, including orphan diseases, cardio-renal disorders, oncology, cell therapy, neurology, anesthesiology, and ophthalmology. He has lectured extensively on life sciences investing and executive management, and is a long-time supporter of patient-advocacy groups. Travis holds a law degree and a chemical engineering degree, both from the University of Wisconsin.

Education